Evidence map›Paper›PMID 40935567›Full record

ArticleJournal for immunotherapy of cancer2025

Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.

Lilach Aizenbud, Noam Savion Gaiger, Ana Luisa Perdigoto, Jacqueline E Mann, Madeline Candelas Torres, Genevieve M Boland, Aleigha R Lawless, Shahar Silverman, David Aaron Schoenfeld, Jodhel I Destina and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lilach Aizenbud *Medical Oncology, Yale University, New Haven, Connecticut, USA.
Noam Savion Gaiger *Medical Oncology, Yale University, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0002-5638-1151
Ana Luisa Perdigoto *Endocrinology and Metabolism, Yale University, New Haven, Connecticut, USA.
Jacqueline E MannMedical Oncology, Yale University, New Haven, Connecticut, USA.
Madeline Candelas TorresEndocrinology and Metabolism, Yale University, New Haven, Connecticut, USA.
Genevieve M BolandDepartment of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
Aleigha R LawlessDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Shahar SilvermanDepartment of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
David Aaron SchoenfeldMedical Oncology, Yale University, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0002-5202-3744
Jodhel I DestinaYale University, New Haven, Connecticut, USA.
Nitzan HassonMedical Oncology, Yale University, New Haven, Connecticut, USA.
Thuy TranMedical Oncology, Yale University, New Haven, Connecticut, USA.ORCID http://orcid.org/0000-0002-6244-7575
Michael HurwitzMedical Oncology, Yale University, New Haven, Connecticut, USA.
Matthew R AustinMedical Oncology, Yale University, New Haven, Connecticut, USA.
Ryan J SullivanMassachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0001-5344-6645
Kevan C HeroldEndocrinology and Metabolism, Yale University, New Haven, Connecticut, USA.
Harriet M KlugerMedical Oncology, Yale University, New Haven, Connecticut, USA Harriet.Kluger@Yale.edu.ORCID http://orcid.org/0000-0002-4932-9873

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI GERALD I SHULMAN · 1993 to 2026
$44.0M
Elucidating mechanisms of checkpoint inhibitor-induced diabetesK08CA282972 · NCI · YALE UNIVERSITY · PI Ana Luisa Jordao Perdigoto · 2023 to 2026
$694k
NCI NIH HHS K08 CA282972NIDDK NIH HHS P30 DK045735
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have improved survival of patients with cancer, yet they pose risks of immune-related adverse events (irAEs). ICI-induced insulin-dependent diabetes mellitus (ICI-DM) is a life-threatening and life-altering irAE. Previously, we reported a high incidence of a germline missense variant in

Indexed as

Histocompatibility Antigens Class IImmune Checkpoint InhibitorsNeoplasmsAdultAgedFemaleHumansIntracellular Signaling Peptides and ProteinsMaleMiddle AgedHistocompatibility Antigens Class IImmune Checkpoint InhibitorsIntracellular Signaling Peptides and ProteinsNLRC5 protein, humanDiabetesImmune Checkpoint InhibitorsImmune related adverse event - irAEMajor histocompatibility complex - MHC

Identifiers

PMID40935567
PMCPMC13059913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.